

Practice News and Alerts

This section of the Oklahoma Board of Nursing website contains information on current topics of concern as well as recently revised statutes and/or rules; newly developed or revised practice guidelines, declaratory rulings and/or positions statements; and newly developed or proposed practice programs. New information will be added to this site on an ongoing basis. Check back frequently!

New information can create a need for clarification. If you have a practice question, the Associate Director of Nursing Practice can be reached at (405) 962-1840. Board staff receives phone calls, electronic communications and visits on a regular basis regarding nursing practice issues and questions.

NEW Prescription Monitoring Program (PMP): Live August 30, 2016

Advanced Practice Registered Nurses with prescriptive authority who plan to prescribe controlled narcotics, schedule III-IV, will need to re-register for this new Prescription Monitoring Program. This software change allows Oklahoma to exchange information with other states easily. The address to register for the PMP is <https://oklahoma.pmpaware.net> . The Support Phone Number is (855-965-4767).

Mandatory Prescription Monitoring Program (PMP) Checks:

The Prescription Monitoring Program (PMP) provides secure access to Oklahoma Bureau of Narcotics registrants, including pharmacies and practitioners in good standing. Regulatory and law enforcement agencies designated by law may also access the system. The PMP application provides continuity between health care practitioners, pharmacies, and state law enforcement to help prevent prescription fraud and drug abuse in Oklahoma

Advanced Practice Registered Nurses with prescriptive authority who prescribe controlled dangerous substance within Oklahoma shall obtain a registration issued by the Director of the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control [63 O.S. § 2-302A].

Registrants shall have access to the central repository, known as the PMP, for the purposes of patient treatment and for determination in prescribing or screening new patients [63 O.S. § 2-309D.G.1.].

Providers may designate a staff member, which could be a licensed nurse, to access the information in the PMP system on the provider's behalf. Individual access is encouraged for each provider and staff member, which allows for identification of the person who has accessed the PMP information. Licensed nurses should not violate the confidentiality of information or knowledge concerning a patient by any means [OAC 485: 10-11-1. (b) (3) (G)].

March, May, July and September 2016 Board Meetings

1. Guidelines Revised:

- a. *Nursing Practice Opinion Requests Procedure*, #P-01 was revised and can be viewed at: <http://nursing.ok.gov//prac-bdopin.pdf> .
- b. *License Verification and Photocopying of Nursing Licenses*, #OBN-02 was revised. Additional clarification on licensure verification is provided in the policy. Information on verification of APRN licensure, certification and prescriptive authority is also provided in the policy. The policy changes can be viewed at: <http://nursing.ok.gov//prac-photocopy.pdf> .
- c. *CRNA Inclusionary Formulary*, #P-50A was revised, removing the drug Droperidol and adding the drugs Sugammadex and Idarucizumaba. Also, an additional cautionary statement was added in regard to Hetastarch, "Avoid use with Renal compromised patients". The changes can be viewed at <http://nursing.ok.gov//prac-crnafrm.pdf> .
- d. *Advanced Practice Registered Nurse (APRN) Certification Examinations Approved by the Oklahoma Board of Nursing*, #P-52A was revised by removing two certification examinations, Advance AIDS Certification for RN and Advanced Oncology Certification for CNS. These two examinations do not meet the initial licensure requirements for APRNs. Both of the certification examinations were added to the *Advanced Practice Registered Nurse Examinations NO Longer Approved by the Oklahoma Board of Nursing*, #P-52B. The changes can be viewed at: <http://nursing.ok.gov//natlcert.pdf> .
- e. *Advanced Practice Registered Nurse Examinations NO Longer Approved by the Oklahoma Board of Nursing*, #P-52B (see above)
- f. *Exclusionary Formulary for Advanced Practice Registered Nurses with Prescriptive Authority*, #P-50B was revised. Changes to the Exclusionary Formulary include the addition of Probuphine and the removal of Droperidol. The formulary can be viewed at: <http://nursing.ok.gov//prac-exclusfrm.pdf> .

Other resources visited frequently include:

Abandonment Statement accessed at: <http://nursing.ok.gov/nursing//prac-aband.pdf>

Decision-Making Model accessed at: <http://nursing.ok.gov/nursing//prac-decmak.pdf>

This guideline can be helpful when attempting to make a practice decision. If you answer all *Decision-Making Model* questions and still are uncertain, you should stop and defer to a qualified practitioner.